Chimeric antigen receptor (CAR) T cell therapy is highly effective in treating hematologic malignancies, and major efforts are being made to achieve similar efficacy in solid tumors. Two landmark events occurred for CAR-T cell therapy in 2017: two anti-CD19 CAR-T cells were approved for the therapy of acute lymphoblastic leukemia (ALL) and relapsed or refractory large B-cell lymphoma,...
CAR-T cells have yielded unprecedented efficacy in B cell malignancies, most remarkably anti-CD19 CAR-T cells for B cell acute lymphoblastic leukemia (B-ALL) with up to a 90% complete remission rate.
The ability to rewire our own immune system to fight cancer has certainly created huge expectations. After the success, more and more preclinical experiments and Phase I-III trials will be...
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek